Notably, the mTORC1 inhibitor rapamycin was shown to reduce tumor growth by suppressing the angiogenic response of endothelial cells to exogenous VEGF-A, suggesting that the mTORC1 pathway downregulates the expression of VEGFRs34. This evidence concerns the gene VEGFA and neoplasm.